Our leadership in COVID-19 testing aimed at detecting variants
November 11, 2021
The flexibility of the PathogenDx Microarray has led to ultra-rapid, low-cost testing to identify specific variants extending the pandemic. Is this information vital? Well, with COVID-19 not going anywhere, we continue to innovate how to deliver greater insight that can help inform point-of-care insights and public health decisions.
Back »
